Literature DB >> 30635287

The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Rein Willemze1, Lorenzo Cerroni2, Werner Kempf3, Emilio Berti4, Fabio Facchetti5, Steven H Swerdlow6, Elaine S Jaffe7.   

Abstract

Primary cutaneous lymphomas are a heterogeneous group of T- and B-cell lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. The 2005 World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) consensus classification has served as a golden standard for the diagnosis and classification of these conditions. In September 2018, an updated version of the WHO-EORTC was published in the fourth edition of the WHO Classification of Skin Tumours Blue Book. In this classification, primary cutaneous acral CD8+ T-cell lymphoma and Epstein-Barr virus positive (EBV+) mucocutaneous ulcer are included as new provisional entities, and a new section on cutaneous forms of chronic active EBV disease has been added. The term "primary cutaneous CD4+ small/medium T-cell lymphoma" was modified to "primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder" because of its indolent clinical behavior and uncertain malignant potential. Modifications have also been made in the sections on lymphomatoid papulosis, increasing the spectrum of histologic and genetic types, and primary cutaneous marginal zone lymphomas recognizing 2 different subtypes. Herein, the characteristic features of these new and modified entities as well as the results of recent molecular studies with diagnostic, prognostic, and/or therapeutic significance for the different types of primary cutaneous lymphomas are reviewed. An update of the frequency and survival of the different types of primary cutaneous lymphomas is provided.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2019        PMID: 30635287      PMCID: PMC6473500          DOI: 10.1182/blood-2018-11-881268

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  77 in total

1.  The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment.

Authors:  Febe van Maldegem; Remco van Dijk; Thera A M Wormhoudt; Philip M Kluin; Rein Willemze; Lorenzo Cerroni; Carel J M van Noesel; Richard J Bende
Journal:  Blood       Date:  2008-08-07       Impact factor: 22.113

2.  Multicenter case series of indolent small/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face.

Authors:  Janet Y Li; Joan Guitart; Melissa P Pulitzer; Antonio Subtil; Uma Sundram; Youn Kim; Janyana Deonizio; Patricia L Myskowski; Alison Moskowitz; Steven Horwitz; Christiane Querfeld
Journal:  Am J Dermatopathol       Date:  2014-05       Impact factor: 1.533

3.  Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.

Authors:  Xiaolong Alan Zhou; Abner Louissaint; Alexander Wenzel; Jingyi Yang; Maria Estela Martinez-Escala; Andrea P Moy; Elizabeth A Morgan; Christian N Paxton; Bo Hong; Erica F Andersen; Joan Guitart; Amir Behdad; Lorenzo Cerroni; David M Weinstock; Jaehyuk Choi
Journal:  J Invest Dermatol       Date:  2018-05-30       Impact factor: 8.551

4.  Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients.

Authors:  Remco van Doorn; Erik Scheffer; Rein Willemze
Journal:  Arch Dermatol       Date:  2002-02

Review 5.  Primary cutaneous B-cell lymphomas with large cell predominance-primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma.

Authors:  Charity B Hope; Laura B Pincus
Journal:  Semin Diagn Pathol       Date:  2016-12-02       Impact factor: 3.464

6.  Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group.

Authors:  S van Santen; R van Doorn; K J Neelis; L A Daniëls; B Horváth; M S Bruijn; C J G Sanders; M M van Rossum; E R M de Haas; J C J M Veraart; M W Bekkenk; M H Vermeer; R Willemze
Journal:  Br J Dermatol       Date:  2017-05-11       Impact factor: 9.302

7.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.

Authors:  Nita Sally Agar; Emma Wedgeworth; Siobhan Crichton; Tracey J Mitchell; Michael Cox; Silvia Ferreira; Alistair Robson; Eduardo Calonje; Catherine M Stefanato; Elizabeth Mary Wain; Bridget Wilkins; Paul A Fields; Alan Dean; Katherine Webb; Julia Scarisbrick; Stephen Morris; Sean J Whittaker
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

8.  Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: A clinicopathologic and immunophenotypical study of 10 cases.

Authors:  Lianne Koens; Nancy J Senff; Maarten H Vermeer; Rein Willemze; Patty M Jansen
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

9.  ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

Authors:  Edgardo R Parrilla Castellar; Elaine S Jaffe; Jonathan W Said; Steven H Swerdlow; Rhett P Ketterling; Ryan A Knudson; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; George Vasmatzis; Sarah E Gibson; Sarah Ondrejka; Alina Nicolae; Karen L Grogg; Cristine Allmer; Kay M Ristow; Wyndham H Wilson; William R Macon; Mark E Law; James R Cerhan; Thomas M Habermann; Stephen M Ansell; Ahmet Dogan; Matthew J Maurer; Andrew L Feldman
Journal:  Blood       Date:  2014-06-03       Impact factor: 22.113

10.  Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases.

Authors:  Helmut Beltraminelli; Bernd Leinweber; Helmut Kerl; Lorenzo Cerroni
Journal:  Am J Dermatopathol       Date:  2009-06       Impact factor: 1.533

View more
  164 in total

1.  Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin.

Authors:  Elisa Milan; Paola Miceli; Alvise Sernicola; Silvia Finotto; Dario Marino; Mauro Alaibac
Journal:  Mol Clin Oncol       Date:  2021-04-15

2.  Interventions for mycosis fungoides.

Authors:  Arash Valipour; Manuel Jäger; Peggy Wu; Jochen Schmitt; Charles Bunch; Tobias Weberschock
Journal:  Cochrane Database Syst Rev       Date:  2020-07-07

Review 3.  Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

Authors:  Alexander Neuwelt; Taha Al-Juhaishi; Eduardo Davila; Bradley Haverkos
Journal:  Blood Adv       Date:  2020-09-08

4.  Total skin electron beam therapy for primary cutaneous T-cell lymphomas: clinical characteristics and outcomes in a Mexican reference center.

Authors:  Ch Flores-Balcázar; D M Urías-Arce; Y Charli-Joseph; M A De León-Alfaro; S I Pérez-Álvarez; R Ramos-Prudencio
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-27

5.  Different aspects and variants of mycosis fungoides in a single patient.

Authors:  Bruno Castro Souza; Denis Miyashiro; Marcelo Abrantes Giannotti; José Antonio Sanches
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 [SEASON]       Impact factor: 2.545

6.  Antibiotics and Imiquimod for Cutaneous T-Cell Lymphoma in Veterans: A Patient Population with Agent Orange Exposure.

Authors:  Christina A Del Guzzo; Arsenije Kojadinovic; Ravi R Vinnakota; Larisa J Geskin; Jessica C Newman; Erik Langhoff; Yeun-Hee A Park; Susan E Bates; Ali N Dana
Journal:  Oncologist       Date:  2021-05-14

7.  Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine.

Authors:  Sophie Voruz; Laurence de Leval; Anne Cairoli
Journal:  Exp Hematol Oncol       Date:  2021-05-13

8.  De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma.

Authors:  Michael Oertel; Khaled Elsayad; Carsten Weishaupt; Kerstin Steinbrink; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2019-11-22       Impact factor: 3.621

9.  ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.

Authors:  Florent Amatore; Nicolas Ortonne; Marc Lopez; Florence Orlanducci; Rémy Castellano; Saskia Ingen-Housz-Oro; Amandine De Croos; Clémentine Salvado; Laurent Gorvel; Armelle Goubard; Yves Collette; Réda Bouabdallah; Jean-Marc Schiano; Nathalie Bonnet; Jean-Jacques Grob; Philippe Gaulard; Martine Bagot; Armand Bensussan; Philippe Berbis; Daniel Olive
Journal:  Blood Adv       Date:  2020-10-27

10.  From Benign Inflammatory Dermatosis to Cutaneous Lymphoma. DNA Copy Number Imbalances in Mycosis Fungoides versus Large Plaque Parapsoriasis.

Authors:  Georgiana Gug; Caius Solovan
Journal:  Medicina (Kaunas)       Date:  2021-05-15       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.